Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02337205
Recruitment Status : Completed
First Posted : January 13, 2015
Last Update Posted : July 6, 2018
Sponsor:
Information provided by (Responsible Party):
Athenex, Inc.

Brief Summary:
This is a phase 1 study to access the safety and tolerability of KX2-391 ointment in subjects who have Actinic Keratosis. This study will also access the amount of KX2-391 drug that enters the blood stream through dermal application of the ointment.

Condition or disease Intervention/treatment Phase
Actinic Keratosis Drug: KX2-391 Ointment Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 29 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Single-Center, Safety, Tolerability, and Pharmacokinetic Study of KX2 391 Ointment in Subjects With Actinic Keratosis
Study Start Date : December 2014
Actual Primary Completion Date : March 2016
Actual Study Completion Date : March 2016

Arm Intervention/treatment
Experimental: KX2-391 Ointment Drug: KX2-391 Ointment
KX2-391 Ointment will be applied at a predetermined concentration to the treatment area for a predetermined time period.




Primary Outcome Measures :
  1. Overall safety and tolerability assessment as determined by laboratory, adverse event (AE) and serious adverse event (SAE) information. [ Time Frame: 45 days ]
    Safety assessments will consist of determining and recording all AEs (including for both increasing and decreasing severity) and SAEs; laboratory evaluation for hematology, blood chemistry, and urine analytes; periodic measurement of vital signs and ECGs; and the performance of physical examinations as detailed in Table 3 of the protocol.

  2. The amount of KX2-391 in the blood stream as determined by pharmacokinetic (PK) analysis: Cmax, Cmin, AUC0-t, AUC0-inf [ Time Frame: 7 days ]
    Individual PK data will be listed by time. Cmax, Cmin, AUC0-t, AUC0-inf will be calculated for KX2-391 to determine systemic exposure.


Secondary Outcome Measures :
  1. Actinic Keratosis (AK) lesion count [ Time Frame: 45 days ]
    The AK lesion count is the investigator's assessment of the number of AK lesions in the treatment area.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject is at least 18 years old
  2. Subject has a clinical diagnosis of stable, clinically typical AK
  3. Subject has a treatment area on 1 dorsal forearm that in:

    Cohort 1:

    • Is one contiguous area
    • Measures 25 cm2
    • Contains 4 to 8 AK lesions that are clinically typical.

    Cohort 2:

    • Is one contiguous area
    • Measures 100 cm2
    • Contains 8 to 16 AK lesions that are clinically typical.
  4. All women of childbearing potential (WOCBP) must be:

    • Post-menopausal, defined as at least 50 years of age with amenorrhea for at least 18 months, or
    • Surgically sterile, defined as having undergone a hysterectomy, bilateral oophorectomy or tubal ligation, or otherwise incapable of pregnancy.
    • Pre or perimenopausal and practicing a highly effective method of birth control, including hormonal prescription, oral contraceptives, contraceptive injections, contraceptive patch, and intrauterine device, for the duration of their participation in the study. Abstinence and double-barrier methods do not qualify as highly effective methods of birth control.
    • All woman of child-bearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day 1 (Visit 2) prior to administration of KX2-391 Ointment dose.

    Contraception

    • Contraception must be consistently used for at least 3 months prior to screening to 3 months after the last KX2-391 Ointment dose.
    • Male Contraception: All men who are sexually active with female partners of child bearing potential must agree to ensure their partners use highly effective contraception and therefore will not father a child from screening to 3 months after the last dose of study medication.
    • Male and Female Contraception: All men and women subjects must agree to not donate sperm or eggs or attempt conception from screening to 3 months after the last KX2-391 Ointment dose.
  5. Subject is, in the opinion of the investigator, in good general health based on medical history, physical examination, electrocardiogram (ECG), and clinical laboratory evaluations at screening.
  6. Subject has clinically acceptable liver function at screening as demonstrated by:

    • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2x upper limit of normal (ULN)
    • Total bilirubin ≤ ULN
  7. No other screening laboratory test, including CBC results, considered clinically significant by the investigator
  8. Subject is not lactating
  9. Subject is willing and able to follow all study instructions and to attend all study visits
  10. Subject is able to comprehend and willing to sign an Informed Consent Form (ICF)

Exclusion Criteria:

  1. Subject has clinically atypical and/or rapidly changing AK lesions on the treatment area
  2. Subject has current systemic malignancy
  3. Subject has used any of the following systemic therapies within the specific period before Visit 1:

    • Retinoids; 180 days
    • Glucocortico-steroids; 28 days
    • Methotrexate or other anti-metabolites; 28 days
  4. Subject has used any of the following topical therapies on the treatment area within the specified period before Visit 1:

    • Retinoids; 90 days
    • Glucocortico-steroids; 14 days
  5. Subject has had any of the following of the AK therapies on the treatment area:

    Medical Therapies within 90 days (or until the site has healed, whichever is longer) before Visit 1:

    • Ingenol mebutate (eg, Picato)
    • 5-fluorouracil (eg, 5-FU; Efudex)
    • Imiquimod (eg, Aldara; Zyclara)
    • Diclofenac with or without hyaluronic acid (eg, Solaraze)
    • Moisturizer, emollients (12 hours prior to Visit 1)

    Surgical Modalities on the treatment area within 30 days (or until the site has healed following treatment, whichever is longer) before Visit 1:

    • Cryotherapy
    • Electrodesiccation
    • Laser, light (eg, photodynamic therapy, intense pulsed light) or any other energy based therapy
    • Chemical peels (eg, tricholoracetic acid)
    • Dermabrasion
    • Surgical removal (eg, curettage, excision)
  6. Subject currently has, or has experienced any of the following on the treatment area within the specified period before Visit 1:

    • A cutaneous malignancy; 180 days
    • Sunburn; 28 days
    • Body art (eg, tattoo, piercing); currently
    • Excessive tan; currently
  7. Subject has a history of sensitivity to any of the ingredients in the study medications
  8. Subject is chronically taking a known strong inhibitor of CYP3A4
  9. Subject has a skin disease (eg, atopic dermatitis, psoriasis, eczema) or condition (eg, scarring, open wounds) that, in the opinion of the investigator, might interfere with the study conduct or evaluations, or which exposes the subject to an unacceptable risk by study participation.
  10. Subject has other significant uncontrolled or unstable medical diseases or conditions that, in the opinion of the investigator, would expose the patient to unacceptable risk from study participation.
  11. Subject has participated in an investigational drug trial during which an investigational study medication was administered within 30 days before Visit 1.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02337205


Locations
Layout table for location information
United States, Texas
DermResearch, Inc.
Austin, Texas, United States, 78759
Sponsors and Collaborators
Athenex, Inc.
Investigators
Layout table for investigator information
Study Director: Douglas Kramer, MD Kinex Pharmaceuticals

Layout table for additonal information
Responsible Party: Athenex, Inc.
ClinicalTrials.gov Identifier: NCT02337205     History of Changes
Other Study ID Numbers: KX01-AK-01-US
First Posted: January 13, 2015    Key Record Dates
Last Update Posted: July 6, 2018
Last Verified: December 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Keratosis
Keratosis, Actinic
Skin Diseases
Precancerous Conditions
Neoplasms